Adagio names David Hering as permanent CEO and Director

seekingalpha2022-07-05

Adagio Therapeutics (NASDAQ:ADGI) has named interim chief executive officer and chief operating officer David Hering, as company’s permanent CEO and a director on the board. “As COVID-19 continues to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2249587005?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-07-05 19:34","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2249587005","market":"us","top_or_hot":-1,"title":"Adagio names David Hering as permanent CEO and Director","media":"seekingalpha","content":"<div>\n<p>Adagio Therapeutics (NASDAQ:ADGI) has named interim chief executive officer and chief operating officer David Hering, as company’s permanent CEO and a director on the board. “As COVID-19 continues to ...</p>\n\n<a href=\"https://seekingalpha.com/news/3854076-adagio-names-david-hering-as-permanent-ceo-and-director\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adagio names David Hering as permanent CEO and Director</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdagio names David Hering as permanent CEO and Director\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-07-05 19:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3854076-adagio-names-david-hering-as-permanent-ceo-and-director><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Adagio Therapeutics (NASDAQ:ADGI) has named interim chief executive officer and chief operating officer David Hering, as company’s permanent CEO and a director on the board. “As COVID-19 continues to ...</p>\n\n<a href=\"https://seekingalpha.com/news/3854076-adagio-names-david-hering-as-permanent-ceo-and-director\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://seekingalpha.com/news/3854076-adagio-names-david-hering-as-permanent-ceo-and-director","article_id":"2249587005","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2249587005","pubTimestamp":1657020851,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Adagio Therapeutics (NASDAQ:ADGI) has named interim chief executive officer and chief operating offi","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4581":"高盛持仓","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4539":"次新股","BK4007":"制药","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓"},"translate_title":"慢板任命大卫·赫林为永久首席执行官兼董事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADGI":1,"BNTX":0.9,"PFE":0.63},"content_text":"Adagio Therapeutics (NASDAQ:ADGI) has named interim chief executive officer and chief operating officer David Hering, as company’s permanent CEO and a director on the board. “As COVID-19 continues to infect millions worldwide, we are committed to the ongoing advancement of Adagio’s founding mission focused on delivering both treatment and prophylactic solutions for COVID-19 and other important infectious diseases,” said Marc Elia, chair of Adagio’s Board of Directors. “A thorough process underlined Dave’s core skills and deep expertise. He is the ideal person to lead Adagio through its next phase of growth, and we are thrilled to appoint him as CEO and director. We believe Adagio has best-in-class antibody discovery and development capabilities and to fully realize its potential the company requires leadership with substantial operational and commercial experience. Dave has a unique track record leading organizations focused on infectious disease medicines, including the launch of the first and market leading COVID-19 vaccine during his time at Pfizer. We are excited about the road ahead for Adagio and the impact we may have on people in need.”  Shares down 3.4% PM.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2249587005"}